Spiriva Respimat: adverse event reports filed with FDA

5,581

reports as suspect product

0% of all reports · about 307 a year

246

reports, 12 months to June 2026

282 in the 12 months before

49.3%

marked serious by the reporter

39.6% across the class

5.7%

record death among outcomes, as reported

320 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Spiriva Respimat reports recording the termmedian drug in anticholinergic

1. Dyspnoeashortness of breath27.3%1,522
2. Asthmaasthma16.7%933
3. Wheezingwheezing11.8%657
4. Coughcough11%612
5. Therapeutic product effect incomplete9.9%552
6. Off label useused for a purpose or in a way not on the label9.5%531
7. Loss of personal independence in daily activities8.3%465
8. Drug ineffectivethe medicine did not work as expected7.5%417
9. Sleep disorder due to a general medical condition7.2%403
10. Chronic obstructive pulmonary diseaseCOPD, a long-term lung disease7%392
11. Pneumonialung infection6.1%339
12. Product quality issuea problem with the product itself5.9%331
13. Chest discomfortchest discomfort4.2%233
14. Obstructive airways disorder3.6%200
15. Productive cougha cough with phlegm3.5%195
16. Blood count abnormal3.4%188
17. Malaisegeneral feeling of being unwell3.3%185
18. Deaththe patient died; cause not stated by this term2.9%163
19. Dizzinesslight-headedness or unsteadiness2.7%153
20. Falla fall2.7%150
21. Fatiguetiredness2.6%146
22. Full blood count abnormal2.5%137
23. Dyspnoea exertional2.3%129
24. Oropharyngeal painsore throat2.3%127
25. Influenzaflu2.2%121
26. Nasopharyngitisa cold2%113
27. Gastrooesophageal reflux diseaseacid reflux1.9%106
28. Nasal congestiona blocked nose1.8%102
29. Headachehead pain1.8%101
30. Chest painchest pain1.8%100

Top 30 of 746 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 24 drugs in the anticholinergic class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 159,807 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 70.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 5,581 reports.

Drugs most often listed in the same reports

Other products listed in reports where Spiriva Respimat is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the anticholinergic class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Spiriva Respimat as a suspect or interacting product; reports listing it only as a concomitant medication (5,564) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.